Biogen posts more Aduhelm biomarker data and a ‘correlation’ with Alzheimer’s clinical benefitnews2021-11-11T17:56:40+00:00November 11th, 2021|Fierce Pharma|
Despite strong efficacy, dermatologist survey indicates Incyte’s Opzelura uptake may face uphill climb: reportnews2021-11-11T16:37:13+00:00November 11th, 2021|Fierce Pharma|
Lundbeck cuts 300 jobs to fuel Vyepti growth as CGRP migraine competition heats upnews2021-11-11T15:20:10+00:00November 11th, 2021|Fierce Pharma|
Baxter CDMO arm to drop $100M to expand fill-finish plant in Germanynews2021-11-11T14:53:04+00:00November 11th, 2021|Fierce Pharma|
Novartis-backed Gamida’s approval plans for cell therapy hits a snag with FDA asking for manufacturing datanews2021-11-11T14:22:36+00:00November 11th, 2021|Fierce Pharma|
EMA flags Johnson & Johnson COVID vaccine for rare disorder, passes mRNA shots for one side effect but probes anothernews2021-11-11T14:22:03+00:00November 11th, 2021|Fierce Pharma|
Seres Therapeutics taps Bacthera to manufacture its lead microbiome therapy at Lonza’s Swiss campusnews2021-11-11T13:19:00+00:00November 11th, 2021|Fierce Pharma|
Johnson & Johnson scores 60-day stay in high-profile talc litigation: reportnews2021-11-10T20:32:01+00:00November 10th, 2021|Fierce Pharma|
Eli Lilly touts long-term safety data for Olumiant amid classwide scrutiny on JAK medsnews2021-11-10T16:30:53+00:00November 10th, 2021|Fierce Pharma|
Merck inks yet another $1B-plus supply deal for COVID pill, this time with Japannews2021-11-10T16:01:28+00:00November 10th, 2021|Fierce Pharma|
